机译:改进索拉非尼治疗肝细胞癌患者的生存预测和预后模型比较
Cancer Center AmsterdamAmsterdam,The Netherlands;
Department of BiostatisticsUniversity of LiverpoolLiverpool,UK;
Department of OncologyCentre Eugène MarquisRennes,FranceDepartment of HepatologyCHU H?pital Saint AndréBordeaux,FranceDepartment of Medicine IIUniversity of FreiburgFreiburg,GermanyUCL Cancer InstituteUniversity College LondonLondon,UKDepartment of SurgeryErasmus MC University Medical CenterRotterdam,The NetherlandsDepartment of Gastroenterology and HepatologyErasmus MC University Medical CenterRotterdam,TheDepartment of Medical OncologyErasmus MC University Medical CenterRotterdam,The NetherlandsDepartment of Medical and Surgical SciencesUniversity of BolognaBologna,ItalyDepartment of Radiology and Nuclear MedicineUniversity of AmsterdamAmsterdam,The NetherlandsDepartment of Medical OncologyUniversity of AmsterdamAmsterdam,The NetherlandsDepartment of Gastroenterology and HepatologyUniversity of AmsterdamAmsterdam,The NetherlandsDepartment of Molecular and Clinical Cancer MedicineUniversity of LiverpoolLiverpool,UK;
hepatocellular carcinoma; model; prediction; prognosis; sorafenib; survival;